Core Viewpoint - 中金辐照's financial performance shows modest growth in revenue and net profit, with a focus on maintaining competitive advantages and expanding market presence in the irradiation technology sector [1][4]. Financial Performance - For the first half of 2025, 中金辐照 reported total revenue of 180 million yuan, a year-on-year increase of 0.58%, and a net profit attributable to shareholders of 65.81 million yuan, up 1.75% [1]. - The gross margin decreased to 61.61%, down 5.24% year-on-year, while the net margin slightly declined to 37.48%, down 0.52% [1]. - The total of selling, administrative, and financial expenses reached 27.57 million yuan, accounting for 15.33% of revenue, an increase of 11.03% year-on-year [1]. Business Strategy and Future Outlook - The company aims to strengthen its market position by enhancing its core competencies and pursuing diversified business development, with a strategic goal of becoming a leading enterprise in health service technology [3][4]. - Future growth drivers include favorable policy environments, increasing market demand in healthcare and food sectors, and ongoing optimization of investment and project development [5][6]. Industry Context - The irradiation technology sector is experiencing rapid expansion, supported by increasing economic scale and market demand, particularly in healthcare, food, and pharmaceuticals [5][6]. - The company operates in a government-encouraged industry, which is expected to benefit from rising consumer demand for high-quality products and services [6].

Core Viewpoint - The company has developed an action plan titled "Enhancing Quality, Increasing Efficiency, and Returning Value" to align with national policies and improve corporate governance, operational efficiency, and shareholder returns [1][2][3]. Group 1: Corporate Governance - The company aims to enhance its governance structure by clarifying the responsibilities and powers of various governance bodies, ensuring effective checks and balances [2][3]. - The company has revised its articles of association and related systems to improve governance and operational standards [1][2]. Group 2: Strategic Focus - The company will focus on core business areas such as nuclear technology applications, digital information, and smart energy to drive growth and market expansion [2][3]. - The company plans to concentrate resources on key sectors to enhance core competitiveness and achieve stable cash flow [2][3]. Group 3: Operational Efficiency - The company intends to reduce costs and improve efficiency by optimizing processes across production, procurement, and operations [3][4]. - The company will streamline operations by eliminating non-core businesses and enhancing overall operational efficiency [3][4]. Group 4: Technological Innovation - The company will prioritize key research projects in nuclear security, smart energy management, and data governance to accelerate the commercialization of technological advancements [4][5]. - The company aims to enhance its R&D capabilities and establish a robust system for technology transfer and commercialization [4][5]. Group 5: Market-Oriented Reforms - The company will deepen reforms to establish a market-oriented operational mechanism, promoting a high-performance culture [5][6]. - The company plans to build a technology talent pool and implement incentive mechanisms to boost innovation [5][6]. Group 6: Modern Industrial System - The company is committed to building a modern industrial system by strengthening core industries and optimizing the industrial structure [6][7]. - The company will integrate resources from the China National Nuclear Corporation to enhance collaboration in energy projects [6][7]. Group 7: New Growth Industries - The company will actively develop strategic emerging industries such as high-end equipment manufacturing and artificial intelligence [6][7]. - The company aims to leverage digital advantages to support the nuclear industry's digital transformation [6][7]. Group 8: Shareholder Returns - The company emphasizes shareholder interests and aims to provide returns based on its operational performance and cash flow [8][9]. - The company will maintain transparent communication with investors to enhance trust and confidence in its long-term growth potential [8][9]. Group 9: Compliance and Communication - The company will strengthen compliance awareness among key personnel and enhance internal management systems [8][9]. - The company will improve information disclosure and investor relations to effectively communicate its value [8][9].

Core Viewpoint - China Tongyuan (01763) has successfully obtained a radiation safety license for its radiation source R&D and production base, marking a significant step in its capability to produce and sell radiation sources [1] Group 1: Project Approval and Capacity - The project is the largest radiation source R&D and production base in Asia, featuring 13 production lines for various radiation sources including Carbon-14 and Krypton-85 [1] - Upon completion, the annual production capacity will exceed 100,000 radiation sources [1] Group 2: Product Offering and Market Impact - The company will consolidate domestic resources for the R&D and production of radiation sources, offering over 70 types of high-quality radionuclide products to both domestic and international markets [1] - Services will include resource recycling and irradiation services, contributing positively to applications in industries such as agriculture, medicine, national defense, and aerospace [1] Group 3: Future Expansion Plans - China Tongyuan plans to promote the second phase of the project to further expand production capacity and diversify its product offerings [1] - New production lines for isotopes such as Californium-252, Cesium-137, and Americium-241 are planned to meet diverse market demands [1]

Core Viewpoint - China Tongfu (01763.HK) has successfully obtained a radiation safety license for its subsidiary Sichuan Nuclear Tongyuan Technology Co., Ltd., enabling it to produce and sell radiation sources, marking a significant step in its operational capabilities [1] Group 1: Project Overview - The project is the largest radiation source research and production base in Asia, featuring 13 production lines for various radiation sources including Carbon-14 and Krypton-85 [1] - Upon completion, the annual production capacity will exceed 100,000 radiation sources [1] Group 2: Product and Service Offerings - China Tongfu aims to consolidate domestic resources for the research and production of radiation sources, offering over 70 types of high-quality radionuclide products to both domestic and international markets [1] - The company will provide services for the reuse of radiation source resources and irradiation services, contributing positively to applications in industries such as agriculture, medicine, national defense, and aerospace [1] Group 3: Future Expansion Plans - The company plans to promote the second phase of the project with high standards to further expand production capacity and diversify its product offerings [1] - Future production lines will include isotopes such as Californium-252, Cesium-137, and Promethium-241 to meet diverse market demands [1]

Core Viewpoint - China Tongyuan (01763) announced that its subsidiary, Sichuan Nuclear Tongyuan Technology Co., Ltd., has successfully obtained a radiation safety license for its radiation source R&D and production base, marking its official qualification for production and sales of radiation sources [1] Group 1: Project Overview - The project is the largest radiation source R&D and production base in Asia, featuring 13 production lines for various radiation sources, including Carbon-14 and Krypton-85 [1] - Upon completion, the annual production capacity will exceed 100,000 radiation sources [1] Group 2: Product and Service Offerings - China Tongyuan will consolidate domestic resources for R&D and production of radiation sources, offering over 70 types of high-quality radiation source products to both domestic and international markets [1] - The company will provide radiation source resource recycling services and irradiation services, contributing positively to applications in industries such as agriculture, medicine, national defense, and aerospace [1] Group 3: Future Plans - The company plans to promote the second phase of the project with high standards to further expand production capacity and diversify its product offerings [1] - Future production lines will include sources such as Californium-252, Cesium-137, and Americium-241 to meet diverse market demands [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 自願性公告 CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1763） 中國同輻放射源研發生產基地成功獲批輻射安全許可證 本公告乃中國同輻股份有限公司（「中國同輻」或「本公司」）自願發出以使股東及潛 在投資者知悉本公司之最新業務進展。 本公司董事會欣然宣佈，近日，中國同輻旗下附屬公司四川中核同源科技有限公 司的放射源研發生產基地「該項目」成功獲批輻射安全許可證，正式具備放射源生 產、銷售等相關資質，產品將逐步面向市場。 該項目是亞洲最大的放射源研發生產基地，建設包括碳-14源、氪-85源等13條放 射源生產線，該項目建成後年產放射源將超過10萬枚。中國同輻將聚集國內主要 放射源的研發、生產資源，向國內外提供超過70種核素的高質量放射源產品，可 提供放射源資源再利用服務、輻照服務等，為我國工業、農業、 ...

Core Viewpoint - The proposed transfer of shares from China Baoyuan Investment Co., Ltd. to China National Nuclear Corporation (CNNC) will enhance CNNC's direct control over China Tongfu (01763) and strengthen its position in the nuclear technology application industry [1][2]. Group 1: Share Transfer Details - China Baoyuan intends to transfer all of its 108 million domestic shares, representing approximately 33.79% of the total issued share capital, to CNNC [1]. - After the proposed transfer, CNNC will directly hold 108 million domestic shares (approximately 33.79% of the total issued share capital) and indirectly hold an additional 128 million domestic shares through various subsidiaries, totaling 236 million domestic shares, which is about 73.83% of the total issued share capital [1]. Group 2: Implications for the Company - Following the proposed transfer, China Baoyuan will no longer be a shareholder, while CNNC will remain the ultimate controlling shareholder of the company [2]. - CNNC's brand influence and industry background are expected to significantly enhance the company's position in technological innovation and market expansion, contributing to high-quality development [2]. - The company is anticipated to play a more critical role and assume greater responsibilities with the support of CNNC, thereby increasing its impact and core competitiveness in the industry [2].

Group 1 - The proposed transfer involves the transfer of 108 million domestic shares (approximately 33.79% of the total issued share capital) from China Baoyuan Investment Co., Ltd. to China National Nuclear Corporation (CNNC) [1][2] - After the proposed transfer, CNNC will directly hold 108 million domestic shares (approximately 33.79% of the total issued share capital) and indirectly hold an additional 128 million domestic shares (approximately 40.04% of the total issued share capital) through various subsidiaries, totaling 236 million domestic shares (approximately 73.83% of the total issued share capital) [1][2] Group 2 - Following the proposed transfer, China Baoyuan will no longer be a shareholder of the company, while CNNC will remain the ultimate controlling shareholder [2] - CNNC is positioned as a national leader in nuclear technology application, which is expected to enhance the company's status, influence, and core competitiveness in technology innovation and market expansion [2]

Core Viewpoint - China Tongfu (01763.HK) announced a proposed transfer of 108,085,353 domestic shares (approximately 33.79% of the total issued share capital) from its controlling shareholder, China Baoyuan Investment Co., Ltd., to its ultimate controlling shareholder, China National Nuclear Corporation (CNNC) [1] Group 1 - After the proposed transfer, CNNC will directly hold 108,085,353 domestic shares (approximately 33.79% of the total issued share capital) and will indirectly hold an additional 128,064,880 domestic shares through its subsidiaries, totaling 236,150,233 domestic shares, which represents approximately 73.83% of the total issued share capital post-transfer [1] - CNNC is recognized as a national leader in nuclear technology applications, and its brand influence and industry background are expected to significantly enhance the company's position, influence, and core competitiveness in technology innovation and market expansion [1] - The support from CNNC will enable the company to play a more critical role, undertake more significant responsibilities, and have a more pronounced impact in the industry [1]

（编辑 袁冠琳） 证券日报网讯 中广核技8月4日在互动平台回答投资者提问时表示，公司积极应对市场竞争，依托"非动 力核技术应用"产业背景，加快新材料产品转型升级节奏，通过强化经营管理、加大市场开发、加速调 整产品结构、推进新产品研发、提升高毛利产品占比等多项措施，提升整体盈利能力和水平。 ...